Skip to main content

Medivir AB chooses Cetara's D360

Certara, a provider of software and scientific consulting services, has announced that Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases, has selected D360 as its global drug discovery platform.

Certara’s D360 is an integrated solution for the query, analysis and visualisation of drug discovery and development data. Medivir will use D360 to deliver research data and analytic tools to its discovery chemists and biologists in Stockholm, Sweden, and Cambridge, UK. The information will be sourced from its existing repository of chemical structure and biological assay data.

‘We were looking for a product that would allow our discovery scientists to collaborate more effectively, and make informed decisions using all the available data,’ said Peter Lind, informatics manager at Medivir.


Media Partners